Literature DB >> 26775146

N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

Fabian Higel1, Andreas Seidl2, Fritz Sörgel3, Wolfgang Friess4.   

Abstract

Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fusion protein; Glyco-engineering; Monoclonal antibody; N-glycosylation; Pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 26775146     DOI: 10.1016/j.ejpb.2016.01.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  63 in total

1.  Conformational Plasticity of the Immunoglobulin Fc Domain in Solution.

Authors:  Soumya G Remesh; Anthony A Armstrong; Andrew D Mahan; Jinquan Luo; Michal Hammel
Journal:  Structure       Date:  2018-05-03       Impact factor: 5.006

2.  Production of functional recombinant cyclic citrullinated peptide monoclonal antibody in transgenic rice cell suspension culture.

Authors:  Do Van Giap; Jae-Wan Jung; Nan-Sun Kim
Journal:  Transgenic Res       Date:  2019-02-11       Impact factor: 2.788

Review 3.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

4.  Characterization of Glycosylated Proteins at Subunit Level by HILIC/MS.

Authors:  Valentina D'Atri; Davy Guillarme
Journal:  Methods Mol Biol       Date:  2021

5.  Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.

Authors:  Yanli Zhuang; Di Chen; Amarnath Sharma; Zhenhua Xu
Journal:  AAPS J       Date:  2018-10-15       Impact factor: 4.009

6.  Antibody characterization using novel ERLIC-MS/MS-based peptide mapping.

Authors:  Jing Zhen; John Kim; Ying Zhou; Ervinas Gaidamauskas; Shyamsundar Subramanian; Ping Feng
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

7.  Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate.

Authors:  Hanna N Wetzel; Rose P Webster; Fatima O Saeed; Terence L Kirley; William J Ball; Andrew B Norman
Journal:  Biochem Biophys Res Commun       Date:  2017-04-23       Impact factor: 3.575

8.  Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm.

Authors:  Dan Boyd; Arpa Ebrahimi; Sarah Ronan; Brian Mickus; Matthew Schenauer; Jenny Wang; Darren Brown; Alexandre Ambrogelly
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

9.  Characterization of Aggregation Propensity of a Human Fc-Fusion Protein Therapeutic by Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors:  Richard Y-C Huang; Roxana E Iacob; Stanley R Krystek; Mi Jin; Hui Wei; Li Tao; Tapan K Das; Adrienne A Tymiak; John R Engen; Guodong Chen
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-15       Impact factor: 3.109

10.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.